Skip to main content
Equibles
BEAM logo

BEAM · Beam Therapeutics Inc.

Track BEAM — free

Use BEAM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BEAM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$25.23 -0.44 (-1.71%) At close · Oct 6
Russell 2000 member Rebalance outlook locked
Market Cap
$2.53B
Shares
103.29M
Volume · Oct 6 2.52M Avg daily vol (3M) 1.97M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$25.23 Open$26.80 Day$24.87–26.94 52W close$20.60–37.92 Avg vol 30d1.9M Short int25.9M · 25.1% float · 12.6d Short vol73% Last earningsFeb 24, 2026 DataFeb 2020–Oct 2026 Filing10-Q · Aug 4

Up next

Latest filing: 10-Q
filed Aug 4, 2026
Q4 2025 earnings call transcript
call held Feb 24, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$156.03M
Trailing 12 months
Net income (TTM)
−$86.52M
Trailing 12 months
Revenue growth YoY
-94.2%
Year over year
Operating margin
-242.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-14.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.05B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.3%
Year over year · more shares
Price change (1Y)
-0.3%
Trailing year
Short interest
25.1%
Latest settlement · 12.6 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15 · calm Equity put/call 0.57
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −11%
below
Price vs 50-day avg −5%
below
RSI (14) 48
neutral
MACD trend Positive
52-week position 27%
mid-range
Momentum
relative strength
Very Weak
1-month return −6%
trailing
6-month return −18%
trailing
YTD return −9%
this year
Relative strength −29%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $27 › 200d $28 — 200d above 50d
Institutional flow Accumulating
2 of 279 funds reported for Sep 30 · net +685 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
25.06% of float · ▲ +0.3% MoM · 12.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
279 holders — near 3-yr high, broad support
Squeeze score 70
elevated · 0–100
Fundamentals
Strong
Revenue growth +33%
Y/Y
EPS growth +82%
Y/Y
Free cash flow $-360.0M
Quant / Vol
risk profile
Very High
Volatility 73%
annualized · 1-yr
Max drawdown −39%
past year
ATR 5.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−11% Bearish
Price vs 50-day avg
−5% Bearish
RSI (14)
48 Neutral
MACD trend
Positive Bullish
52-week position
27% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $27 › 200d $28 — 200d above 50d
Institutional flow Accumulating
2 of 279 funds reported for Sep 30 · net +685 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
25.06% of float · ▲ +0.3% MoM · 12.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
279 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $21 Now $25 · 27% Range high $38
vs 200-day avg -11% vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BEAM
Beam Therapeutics Inc.
this stock
$2.53B -9.0% +33.3% — 25.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +10.8% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.3% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +535.7% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
279
% held
106.7%
Reported
2 of 279
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
263
View
Short & Settlement
Short Interest Rising
Shares short
25.9M
Days to cover
12.6d
Change
+82.1K sh
View
Short Volume
Short vol %
73%
As of
Oct 6, 2026
Short Total
View
Fails to Deliver
FTD shares
2.9K
Value
$86.3K
As of
Sep 4, 2026
View
Off-Exchange
Off-exchange %
46.5%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$139.7M
Net income (FY)
$-80.0M
EPS diluted
$-0.81
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 8, 2026
This year
13
View
Proposed Sales
Value
$429.3K
Shares
16.7K
Filed
Jul 27, 2026
View
Earnings & Events
Webcasts
Last webcast
Sep 8, 2026
View

Performance

5D 20D 120D MTD YTD
BEAM +2.9% -6.0% -17.8% +3.2% -9.0%
SPY +2.0% +1.7% +11.3% +2.2% +14.3%
vs SPY +1.0% -7.7% -29.1% +1.0% -23.2%
Key facts CIK 1745999 CUSIP 07373V105 13F (30d) 6 filings 6 filers Visit website Investor relations